Logo
ABBV logo
AbbVie Inc.
ABBV
218.73 (0.33%) 0.73
Health Care
Biotechnology
AbbVie Inc. a research-based biopharmaceutical company engages in the research and development manufacture commercialization and sale of medicines and therapies worldwide. The company offers Humira an injection for autoimmune and intestinal Behçet's diseases generalized pustular psoriasis and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases erythrodermic psoriasis generalized pustular psoriasis and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables plastics and regenerative medicine body contouring and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia bipolar disorder and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine as well as other neuroscience products. In addition the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago Illinois.

Quality Checklist 1/8

Est. EPS Growth > 5%
5Y Shares Out Change < 0%
ROIC > 10%
Debt/Equity < 1
Current Ratio > 1
Quick Ratio > 1
Net Margin > 10%
Past Net Income CAGR > 0%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $386.58(B)
EV: $432.03(B)
Total Equity: $-2.60(B)
Earnings date: Feb-04-2026
P/E: 164.46
Forward P/E: 20.99
P/FCF: 19.63
P/S: 6.49
P/B: N/A
EPS: $1.3
EPS (fwd): $10.4
FCF/share: $11.1
Revenue/share: $33.7
Book value/share: $-1.5
ROIC: 3.3%
ROA: 1.7%
ROE: 140.9%
Debt/Equity: 48
Current Ratio: 0.70
Gross margin: 71.5%
Operating margin: 24.1%
Net margin: 4.0%
Dividend/share: $6.6
Div. yield: 3.00%
All Valuation Overview Growth Financials & KPIsCompetitors & Peer Comparison Ownership Tools

ABBV Valuation & Price Targets

Current Price
$219

Favorite Valuation Methods

PEvaluation
N/A
Analyst targets
N/A
DCF (2-stage)
N/A

More Valuation Methods

DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A

PEvaluation

9% overvalued
Low
$149
Mid
$199
High
$248
Current price
$219
Fair P/E
Margin of safety
EPS
Market Model
ROICRevenue growthFCF MarginShares outstan...Debt/EquityDebt/EBITDA
Economic moat: Wide

EPS Estimates

LowAvgHigh#
FY+19.910.410.618
FY+213.314.215.128
FY+314.615.917.424
FY+415.617.519.615
FY+515.818.821.514

Analyst Price Targets

12% undervalued
Low
$184
Mid
$245
High
$289
Current price
$219

Analyst Recommendations

Strong Buy6
Buy13
Hold9
Sell0
Strong Sell1

2-stage DCF

First Stage Duration: 5 Years
Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh
Terminal Growth Rate
LowMidHigh
Discount Rate

Discounted Cash Flow

Forecast years: 5 Years
Terminal Growth Rate
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years
Exit FCF Multiple
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years
First Stage Growth Rate
Final Growth Rate
Discount Rate

EPS Growth

Forecast years: 5 Years
Starting EPS
EPS Growth Rate
LowMidHigh
Final P/E
LowMidHigh
Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years
Base Revenue
Revenue Growth Rate
LowMidHigh
Final Net Margin
LowMidHigh
Final P/E Ratio
LowMidHigh
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate

TTM Financials

Income (TTM)

RevenueGrossNet
Revenue$59.64(B)
Gross profit$42.62(B)
EBITDA$29.52(B)
Net income$2.39(B)
Gross margin71.5%
Operating margin24.1%
Net margin4.0%
Shares outstanding1.77(B)

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsEquityCurrent liabilitiesLong term debtOther LT liabilities
Total assets$133.90(B)
Current assets$28.54(B)
Total liabilities$136.50(B)
Current liabilities$39.39(B)
Cash & Short-term inv.$5.67(B)
Long-term debt$63.08(B)
Total intangibles$89.94(B)
PP&E$5.48(B)

Cash flow (TTM)

CFOCFICFF
FCF$19.68(B)
CapEx$-1.18(B)
Dividends paid$-11.50(B)
Stock issued$134.00(M)
Stock repurchased$-1.33(B)
Stock-based comp.$1.47(B)
Debt issued$11.79(B)
Debt repaid$-14.56(B)

Per share data (TTM)

Price: $219
Revenue: $33.7 (6.5x | 15.4%) Gross profit: $24.1 (9.1x | 11.0%) Earnings: $1.33 (164.5x | 0.6%)
FCF: $11.1 (19.6x | 5.1%) Stock-based Comp.: $0.83 (262.6x | 0.4%) CapEx.: $0.67 (328.7x | 0.3%) Dividend: $6.56 (33.3x | 3.0%)
Total Assets: $75.8 (2.9x | 34.6%) Total Liabilities: $77.2 (2.8x | 35.3%) Book Value: $-1.49 (-146.8x | -0.7%) Cash & ST inv.: $3.21 (68.2x | 1.5%) Debt: $35.7 (6.1x | 16.3%)
Earnings FY+1: $10.4 (21.0x | 4.8%) Earnings FY+2: $14.2 (15.4x | 6.5%) Earnings FY+3: $15.9 (13.8x | 7.3%) Earnings FY+4: $17.5 (12.5x | 8.0%) Earnings FY+5: $18.8 (11.6x | 8.6%)
FCF FY+1: $10.3 (21.3x | 4.7%) FCF FY+2: $14.7 (14.9x | 6.7%) FCF FY+3: $15.6 (14.0x | 7.1%) FCF FY+4: $16.6 (13.2x | 7.6%) FCF FY+5: $18.0 (12.1x | 8.2%)

Summary

Growth Estimates

Revenue

CAGR: 7.2%
FY+1FY+2FY+3FY+4FY+5
FY+1$60.93(B)
FY+2(+9.5%)$66.72(B)
FY+3(+7.8%)$71.90(B)
FY+4(+6.9%)$76.85(B)
FY+5(+4.8%)$80.51(B)

Net Income

CAGR: 16.0%
FY+1FY+2FY+3FY+4FY+5
FY+1$17.97(B)
FY+2(+39.8%)$25.13(B)
FY+3(+11.4%)$27.98(B)
FY+4(+9.4%)$30.60(B)
FY+5(+6.4%)$32.58(B)

EPS

CAGR: 15.9%
FY+1FY+2FY+3FY+4FY+5
FY+1$10.42
FY+2(+36.7%)$14.24
FY+3(+11.6%)$15.89
FY+4(+10.3%)$17.53
FY+5(+7.4%)$18.82

FCF per share

CAGR: 15.0%
FY+1FY+2FY+3FY+4FY+5
FY+1$10.29
FY+2(+42.5%)$14.66
FY+3(+6.2%)$15.57
FY+4(+6.4%)$16.56
FY+5(+8.8%)$18.01

Historical Financials

Showing limited histrical data.
TTM (Y)TTM (Q)FYFQ
Income(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.010.0(B)20.0(B)30.0(B)40.0(B)50.0(B)
Revenue Operating Income Net IncomeCOGSGross ProfitTotal OpEx.R&DSG&AInterest ExpenseInterest IncomeOther Non-operating IncomePre-tax incomeIncome tax
Cash flow(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.05.0(B)10.0(B)15.0(B)20.0(B)
Stock-based Comp. FCFCFONet IncomeD&AChange in Working CapitalCFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.020.0(B)40.0(B)60.0(B)80.0(B)100.0(B)120.0(B)140.0(B)
Total Assets Total LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EIntangible AssetsGoodwillCurrent liabilitiesShort-Term DebtAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Per share data(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.02.04.06.08.010.012.0
EPS (Basic) FCF/Share Dividend/ShareEPS (Diluted)Book value/ShareCash & ST inv./ShareDebt/Share
Ratios(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.020.040.060.080.0100.0
P/E P/S EV/EarningsP/FCFP/BEV/FCFDebt/EquityPayout ratio
Margins(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0%10%20%30%40%50%60%70%
Net Income Margin Operating Margin Gross MarginEBITDA MarginFCF Margin
Returns(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0%2%4%6%8%10%12%14%
ROIC ROAROCEROE
Shares outstanding(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.0500.0(M)1.0(B)1.5(B)
Shares (Basic)Shares (Diluted)
Market Cap.(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.0100.0(B)200.0(B)300.0(B)400.0(B)
Market Cap.

KPIs

Revenue By Geography(show more...)
12/20223/20236/20239/202312/20233/20246/20249/202412/20243/2025
US International
Revenue By Segment(show more...)
12/20223/20236/20239/202312/20233/20246/20249/202412/20243/2025
Neuroscience Immunology Women's Health Hematologic Oncology Aesthetics Other Products HCV Eye Care

ABBV vs Peers

Similar Companies

Ownership

Major holders

*Excludes indirect insider ownership

Insiders: 0.10%
Institutions: 75.14%
Other: 24.76%

Institutional ownership

10.06% Vanguard Group Inc8.26% Blackrock Inc.6.40% JPMORGAN CHASE & CO4.52% State Street Corporati...2.36% Morgan Stanley2.29% Geode Capital Manageme...1.47% Charles Schwab Investm...1.43% Capital Research Globa...1.42% Bank of America Corpor...1.31% NORGES BANK35.62% Others

Trading Summary

In the past year, insiders have bought $0.00 worth of the company's stock, and sold $68.78(M).

Congress members have bought between $102025 - $530000 worth of the company's stock, and sold between $85022 - $450000.

Insider transactions

$0.002026-02$0.00
$0.002026-01$0.00
$0.002025-12$0.00
$0.002025-11$0.00
$0.002025-10$0.00
$0.002025-09$0.00
$11.05(M)2025-08$0.00
$0.002025-07$0.00
$0.002025-06$0.00
$0.002025-05$0.00
$0.002025-04$0.00
$46.66(M)2025-03$0.00
$11.07(M)2025-02$0.00
DateSharesTotal ($)Price ($)NameTitle
Grant2025-08-1242,3702,324,41854.9SALEKI-GERHARDT AZITAChief Operating Officer
Sell2025-08-1242,3708,407,055198.4SALEKI-GERHARDT AZITAChief Operating Officer
Sell2025-08-0513,2952,639,253198.5DONOGHOE NICHOLASOfficer
Grant2025-05-091,20300.0WADDELL FREDERICK HDirector
Grant2025-05-091,20300.0FREYMAN THOMAS CDirector
Grant2025-05-091,20300.0FALK THOMAS JDirector
Grant2025-05-091,20300.0AUSTIN ROXANNE SCHUHDirector
Grant2025-05-091,20300.0TILTON GLENN FLETCHERDirector
Grant2025-05-091,20300.0ALPERN ROBERT JDirector
Grant2025-05-091,20300.0HART BRETT JDirector
Grant2025-05-091,20300.0RAPP EDWARD JDirector
Grant2025-05-091,20300.0ROBERTS REBECCA B.Director
Grant2025-05-091,20300.0BURNSIDE WILLIAM H LDirector
Grant2025-05-091,20300.0MEYER MELODY BDirector
Grant2025-05-091,20300.0DAVIS JENNIFER LDirector
Grant2025-05-091,20300.0QUAGGIN SUSAN EDirector
Grant2025-03-3125,7002,030,81479.0STEWART JEFFREY RYANOfficer
Sell2025-03-3158,83212,359,504210.1STEWART JEFFREY RYANOfficer
Grant2025-03-312,45000.0GONZALEZ RICHARD ADirector
Sell2025-03-1417,6443,746,527212.3REENTS SCOTT T.Chief Financial Officer
Grant2025-03-0318,0082,879,040159.9SIATIS PERRY C.General Counsel
Sell2025-03-0398,62820,263,020205.4GONZALEZ RICHARD ADirector
Sell2025-03-0321,2504,472,039210.4RICHMOND TIMOTHY JOfficer
Sell2025-03-0327,9005,822,402208.7SIATIS PERRY C.General Counsel
Grant2025-02-2622,2102,539,936114.4RICHMOND TIMOTHY JOfficer
Grant2025-02-2616,2601,601,31398.5BUCKBEE KEVIN KOfficer
Sell2025-02-2629,9176,070,036202.9RICHMOND TIMOTHY JOfficer
Sell2025-02-2618,9443,853,372203.4BUCKBEE KEVIN KOfficer
Sell2025-02-205,7781,143,453197.9SIATIS PERRY C.General Counsel
Grant2025-02-13171,83700.0GONZALEZ RICHARD ADirector
Grant2025-02-1338,15400.0RICHMOND TIMOTHY JOfficer
Grant2025-02-1345,65100.0STEWART JEFFREY RYANOfficer
Grant2025-02-1338,49800.0SALEKI-GERHARDT AZITAChief Operating Officer
Grant2025-02-1310,55500.0THAKKAR ROOPALOfficer
Grant2025-02-1361,36200.0MICHAEL ROBERT A.Chief Executive Officer
Grant2025-02-1325,34500.0DONOGHOE NICHOLASOfficer
Grant2025-02-1324,76300.0REENTS SCOTT T.Chief Financial Officer
Grant2025-02-1317,76200.0SIATIS PERRY C.General Counsel
Grant2025-02-138,34700.0BUCKBEE KEVIN KOfficer

Congressional trading

$0.002026-02$0.00
$0.002026-01$0.00
$0.002025-12$0.00
$80012025-11$0.00
$160012025-10$16001
$0.002025-09$0.00
$240022025-08$24002
$160012025-07$24002
$0.002025-06$16001
$0.002025-05$56502
$1555042025-04$24002
$0.002025-03$16001
$400032025-02$115502
DatePoliticianPartyChamberAmount ($)
Sell2025-11-13Julie JohnsonDHouse$1,001 - $15,000
Sell2025-10-31Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-08-22John BoozmanRSenate$1,001 - $15,000
Sell2025-08-14Julie JohnsonDHouse$1,001 - $15,000
Sell2025-08-11John BoozmanRSenate$1,001 - $15,000
Buy2025-08-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-08-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-08-04Marjorie Taylor GreeneRHouse$1,001 - $15,000
Buy2025-07-22Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-07-22Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-07-11Ritchie TorresDHouse$1,001 - $15,000
Buy2025-07-01Ro KhannaDHouse$1,001 - $15,000
Buy2025-07-01Ro KhannaDHouse$1,001 - $15,000
Buy2025-06-17Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-06-17Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-05-28Ro KhannaDHouse$15,001 - $50,000
Buy2025-05-22Josh GottheimerDHouse$1,001 - $15,000
Buy2025-05-15Rob BresnahanRHouse$1,001 - $15,000
Buy2025-05-05Marjorie Taylor GreeneRHouse$1,001 - $15,000
Sell2025-04-17Josh GottheimerDHouse$1,001 - $15,000
Sell2025-04-17Jefferson ShreveRHouse$50,001 - $100,000
Sell2025-04-09Ro KhannaDHouse$15,001 - $50,000
Sell2025-04-08Rob BresnahanRHouse$1,001 - $15,000
Buy2025-04-07Jared MoskowitzDHouse$1,001 - $15,000
Sell2025-04-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-04-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-04-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-04-03Josh GottheimerDHouse$1,001 - $15,000
Sell2025-04-03Dwight EvansDHouse$1,001 - $15,000
Buy2025-04-01Josh GottheimerDHouse$1,001 - $15,000
Buy2025-03-17Marjorie Taylor GreeneRHouse$1,001 - $15,000
Buy2025-03-06Ro KhannaDHouse$1,001 - $15,000
Buy2025-02-25Rob BresnahanRHouse$1,001 - $15,000
Buy2025-02-24Jefferson ShreveRHouse$50,001 - $100,000
Buy2025-02-19Ro KhannaDHouse$15,001 - $50,000
Sell2025-02-05Ro KhannaDHouse$1,001 - $15,000
Sell2025-02-05Ro KhannaDHouse$1,001 - $15,000
Sell2025-02-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-02-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-02-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-01-22Ro KhannaDHouse$1,001 - $15,000
Sell2025-01-17Ro KhannaDHouse$1,001 - $15,000
Buy2025-01-15Jared MoskowitzDHouse$1,001 - $15,000
Buy2025-01-15Jared MoskowitzDHouse$1,001 - $15,000

Tools

Dividend Income

Investment Amount
Dividend Yield
What is the Dividend Income Calculator?

The Dividend Income Calculator helps you estimate the yearly, quarterly, monthly, and daily income of your investments.

How to Use This Calculator?

Enter the dividend yield and the invested amount. Optionally, preload stock data to automatically fetch the dividend yield.

Required Investment

Dividend Yield
Desired Yearly Payout
Desired Quarterly Payout
Desired Monthly Payout
What is the Required Investment Calculator?

The Required Investment Calculator helps you determine the amount of money you need to invest in a stock to achieve a desired dividend.

How to Use This Calculator?

Enter the dividend yield and your desired dividend income. Optionally, preload stock data to automatically fetch the dividend yield.

Future Dividend Yield

Base Dividend
Current Price
Number of Years
Dividend Growth Rate
What is the Future Yield Calculator?

The Future Yield Calculator helps you estimate the future dividend yield of a stock based on its current dividend, price, and expected dividend growth rate.

How to Use This Calculator?

Enter the base dividend, current price, number of years, and dividend growth rate. Optionally, preload stock data to automatically fetch the dividend and price. The calculator will display the current yield and the projected future yield.

Future Dividend Income

Base Dividend
Number of Years
Dividend Growth Rate
What is the Future Dividend Income Calculator?

The Future Dividend Income Calculator helps you estimate the future dividend income from your investments based on the current dividend yield and expected growth rate.

How to Use This Calculator?

Enter the current dividend yield, expected growth rate, and investment duration. Optionally, preload stock data to automatically fetch the dividend yield.

(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact